Targeted tumor therapies at a glance

Current Drug Targets

Volumn 10, Issue 2, 2009, Pages 89-93

  Fuchs, Hendrik ^a   Bachran, Christopher ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; Prodrug; Targeted toxins; Tumor therapy

Indexed keywords

4 [N,N BIS(2 IODOETHYL)AMINO]PHENOXYCARBONYL GLUTAMIC ACID; ADENOSINE DIPHOSPHATE RIBOSE; BL 22; BL22; CAT 3888; CAT 8015; CINTREDEKIN BESUDOTOX; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; FLUDARABINE; GELONIN; GEMTUZUMAB OZOGAMICIN; HA 22; HD37 DGA; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IMMUNOTOXIN LMB1; IMMUNOTOXIN LMB2; IMMUNOTOXIN LMB7; IMMUNOTOXIN LMB9; IMTOX 19; IMTOX 22; IMTOX 25; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; NBI 3001; PSEUDOMONAS EXOTOXIN; RFB4 DGA; RFT5 DGA; RIBOSOME INACTIVATING PROTEIN; SAPORIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TP 38; TP 40; UNCLASSIFIED DRUG; UNINDEXED DRUG; XOMAZYME; ZD 2767P; BACTERIAL TOXIN; PRODRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ADENOCARCINOMA; ADVANCED CANCER; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLADDER CANCER; BRAIN TUMOR; BREAST TUMOR; CANCER CHEMOTHERAPY; CARCINOMA IN SITU; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; CUTANEOUS T CELL LYMPHOMA; DRUG CONJUGATION; DRUG RESPONSE; ENZYME PRODRUG THERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TARGETING; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; KIDNEY TUMOR; LEUKEMIA; LEUKEMIA REMISSION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOMA; MELANOMA; NONHODGKIN LYMPHOMA; POLYMER DIRECTED ENZYME PRODRUG THERAPY; PROLYMPHOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN TARGETING; RECOMBINANT DNA TECHNOLOGY; REVIEW; DRUG DELIVERY SYSTEM; NEOPLASM;

BACTERIAL TOXINS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PRODRUGS;

EID: 64249088444     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009787354557     Document Type: Review

References (33)

1. Mathe, G.; Tran Ba, L.O. and Bernard, J. (1958) C R Hebd. Seances Acad. Sci. 246(10), 1626-1628.
2. Carter, P. (2001) Nat. Rev. Cancer, 1(2), 118-129.
3. Ludwig, D.L.; Pereira, D.S.; Zhu, Z.; Hicklin, D.J. and Bohlen, P. (2003) Oncogene. 22(56), 9097-9106.
4. Murphy, J.R.; Williams, D.P.; Bacha, P.; Bishai, W.; Waters, C. and Strom, T.B. (1988) J. Recept. Res. 8(1-4), 467-480.
5. Ahn, G.O. and Brown, M. (2007) Front Biosci. 12, 3483-3501.
6. Bagshawe, K.D. (2006) Expert Rev. Anticancer Ther. 6(10), 1421-1431.
7. Houston, T.A. (2007) Curr. Drug Deliv. 4(4), 264-268.
8. Zhang, Q.; Xiang, G.; Zhang, Y.; Yang, K.; Fan, W.; Lin, J.; Zeng, F. and Wu, J. (2006) J. Pharm. Sci. 95(10), 2266-2275.
9. Matsumura, Y.; Oda, T. and Maeda, H. (1987) Gan To Kagaku Ryoho. 14(3 Pt 2), 821-829.
10. Altaner, C. (2008) Cancer Lett. 270(2), 191-201.
11. Dalley, D.N. (2008) A Phase I, Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate, U.S. National Institutes of Health, NCT00625430.
12. Schrama, D.; Reisfeld, R.A. and Becker, J.C. (2006) Nat. Rev. Drug Discov. 5(2), 147-159.
13. Alfano, R.W.; Leppla, S.H.; Liu, S.; Bugge, T.H.; Duesbery, N.S. and Frankel, A.E. (2008) Cell Cycle 7(6), 745-749.
14. Moolten, F.L. and Cooperband, S.R. (1970) Science 169(940), 68-70.
15. Blythman, H.E.; Casellas, P.; Gros, O.; Gros, P.; Jansen, F.K.; Paolucci, F.; Pau, B. and Vidal, H. (1981) Nature 290(5802), 145-146.
16. Iglewski, B.H.; Liu, P.V. and Kabat, D. (1977) Infect. Immun. 15(1), 138-144.
17. Van Ness, B.G.; Howard, J.B. and Bodley, J.W. (1980) J. Biol. Chem. 255(22), 10717-10720.
18. Kreitman, R.J. (2006) AAPS J. 8(3), E532-551.
19. Kreitman, R.J. and Pastan, I. (2006) Curr. Drug Targets 7(10), 1301-1311.
20. Pastan, I.; Hassan, R.; Fitzgerald, D.J. and Kreitman, R.J. (2006) Nat. Rev. Cancer 6(7), 559-565.
21. Pastan, I.; Hassan, R.; FitzGerald, D.J. and Kreitman, R.J. (2007) Annu. Rev. Med. 58, 221-237.
22. Frankel, A.E. (2008) A Phase I/II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Surface CD3+ Malignant T Cell Diseases, U.S. National Institutes of Health, NCT00611208.
23. Coutre, S.E.; Tallman, M.; Kreitman, R.J.; Robak, T. and Dearden, C. (2007) A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL), U.S. National Institutes of Health, NCT00462189.
24. Rosen, P.; Cripe, L.; Kreitman, R.J. and Robak, T. (2007) A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL), U.S. National Institutes of Health, NCT00457860.
25. Endo, Y.; Mitsui, K.; Motizuki, M. and Tsurugi, K. (1987) J. Biol. Chem. 262(12), 5908-5912.
26. Cortes, J. (2008) Phase I Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies, U.S. National Institutes of Health, NCT00038051.
27. Schattenberg, A.V. (2008) A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins for the Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease, U.S. National Institutes of Health, NCT00640497.
28. Verma, A. (2007) A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia, U.S. National Institutes of Health, NCT00450944.
29. Baluna, R.; Rizo, J.; Gordon, B.E.; Ghetie, V. and Vitetta, E.S. (1999) Proc. Natl. Acad. Sci. USA, 96(7), 3957-3962.
30. Stewart, K.M.; Horton, K.L. and Kelley, S.O. (2008) Org. Biomol. Chem. 6(13), 2242-2255.
31. Hetzel, C.; Bachran, C.; Fischer, R.; Fuchs, H.; Barth, S. and Stocker, M. (2008) J. Immunother. 31(4), 370-376.
32. Fuchs, H.; Bachran, C.; Li, T.; Heisler, I.; Durkop, H. and Sutherland, M. (2007) J. Control Release 117(3), 342-350.
33. Kreitman, R.J.; Squires, D.R.; Stetler-Stevenson, M.; Noel, P.; FitzGerald, D.J.; Wilson, W.H. and Pastan, I. (2005) J. Clin. Oncol. 23(27), 6719-6729.